Você pesquisou por y - Revista Brasileira de Ginecologia e Obstetrícia
You searched for:"Pedro Martins Bellei"
We found (2) results for your search.Summary
Rev Bras Ginecol Obstet. 2012;34(1):22-27
DOI 10.1590/S0100-72032012000100005
PURPOSE: Evaluate the effects of ipriflavone during fetogenesis, since no studies have been conducted to assess its effect during this period. METHODS: 60 pregnant rats were divided randomly into four groups (n=15). G-control (1 mL of distilled water) and three groups treated intragastrically with ipriflavone from the 16th to the 20th post coitus (PC) day: G-300 (300 mg/kg), G-1,500 (1,500 mg/kg) and G-3,000 (3,000 mg/kg). The animals were weighed, anaesthetized intraperitoneally with xylazine and ketamine at doses of 180 mg/kg and 10 mg/kg, respectively, and sacrificed by total exsanguination on the 21st day. A complete blood count was performed and serum cholesterol, triglycerides, AST, ALT, urea, creatinine, and glucose were determined in pregnant rats. After laparotomy, the liver, kidneys, adrenals, spleen and ovaries were removed and weighed; fetuses and placentas were also weighed to obtain the average weight of the litters. Four fetuses (two males and two females) were chosen at random for the determination of the length and weight of brain, liver, kidneys and lungs. Statistical analysis: ANOVA followed by Dunnett's test. For raw data without normal distribution and homoscedasticity, we used the Kruskal-Wallis test followed by the Mann-Whitney test. Proportions were analyzed by the χ² test (p<0.05). RESULTS: Triglyceride levels (mg/dL) were: Control-G (138.8±21.8), G-300 (211.2±63.9) G-1,500 (251.5±65.2) G-3,000 (217.7±49.6); p<0.05. The body weight of fetuses (g) was: G-Control (male 3.3±0.3; female 3.1±0.3), G-300 (male 3.4±0.2; female 3.1±0.4), G-1,500 (male 3.5±0.3; female 3.2±0.3), G-3,000 (male 3.4±0.5; female 3.1±0.4). CONCLUSION: Ipriflavone did not cause maternal toxicity, but increased triglyceride levels and reduced hematocrit at higher doses. The body and organ weights of the fetuses did not change with dam treatment. There were no external malformations or fetal deaths.
Summary
Rev Bras Ginecol Obstet. 2012;34(1):22-27
DOI 10.1590/S0100-72032012000100005
PURPOSE: Evaluate the effects of ipriflavone during fetogenesis, since no studies have been conducted to assess its effect during this period. METHODS: 60 pregnant rats were divided randomly into four groups (n=15). G-control (1 mL of distilled water) and three groups treated intragastrically with ipriflavone from the 16th to the 20th post coitus (PC) day: G-300 (300 mg/kg), G-1,500 (1,500 mg/kg) and G-3,000 (3,000 mg/kg). The animals were weighed, anaesthetized intraperitoneally with xylazine and ketamine at doses of 180 mg/kg and 10 mg/kg, respectively, and sacrificed by total exsanguination on the 21st day. A complete blood count was performed and serum cholesterol, triglycerides, AST, ALT, urea, creatinine, and glucose were determined in pregnant rats. After laparotomy, the liver, kidneys, adrenals, spleen and ovaries were removed and weighed; fetuses and placentas were also weighed to obtain the average weight of the litters. Four fetuses (two males and two females) were chosen at random for the determination of the length and weight of brain, liver, kidneys and lungs. Statistical analysis: ANOVA followed by Dunnett's test. For raw data without normal distribution and homoscedasticity, we used the Kruskal-Wallis test followed by the Mann-Whitney test. Proportions were analyzed by the χ² test (p<0.05). RESULTS: Triglyceride levels (mg/dL) were: Control-G (138.8±21.8), G-300 (211.2±63.9) G-1,500 (251.5±65.2) G-3,000 (217.7±49.6); p<0.05. The body weight of fetuses (g) was: G-Control (male 3.3±0.3; female 3.1±0.3), G-300 (male 3.4±0.2; female 3.1±0.4), G-1,500 (male 3.5±0.3; female 3.2±0.3), G-3,000 (male 3.4±0.5; female 3.1±0.4). CONCLUSION: Ipriflavone did not cause maternal toxicity, but increased triglyceride levels and reduced hematocrit at higher doses. The body and organ weights of the fetuses did not change with dam treatment. There were no external malformations or fetal deaths.
Summary
Rev Bras Ginecol Obstet. 2008;30(7):335-340
DOI 10.1590/S0100-72032008000700003
PURPOSE: to evaluate the effect of exposure of female rats to therapeutic ultrasound in the pre-implantation phase. METHODS: pregnant Wistar female rats have been exposed to 3 MHz, 0.6 W/cm² ultrasound, pulsatile ultrasound (PUS) or continuous ultrasound (CUS), and controls, unplugged ultrasound (UUS), for five minutes. The rats were sacrificed at the 20th day post-insemination. Biochemical and hematological analyses have been done. Animals have been submitted to necropsy in order to identify lesions of internal organs, and to remove and weight the liver, kidneys and ovaries. Alive, malformed, dead and reabsorbed fetuses have been counted. RESULTS: the rats have not presented changes in their body and organs weight, and neither in their reproductive capacity, but there has been an increase in triglycerides in the PUS and CUS groups, when compared to the UUS group. The fetuses' relative weights of the heart (0.7 ± 0.9), liver (9.8 ± 0.8), kidneys (6.2 ± 0.8) and lungs (3.8 ± 0.4) increased in the CUS, when compared to the heart (0.7 ± 0.9), liver (9.8 ± 0.8), kidneys (6.2 ± 0.8) e lungs (3.8 ± 0.4) of the UUS. CONCLUSIONS: in the experimental model, the therapeutic ultrasound used has not caused meaningful maternal toxicity. Pulsatile waves have not changed fetal morphology, but continuous waves have caused increase in the relative weight of the fetuses' heart, liver, lungs and kidneys.
Summary
Rev Bras Ginecol Obstet. 2008;30(7):335-340
DOI 10.1590/S0100-72032008000700003
PURPOSE: to evaluate the effect of exposure of female rats to therapeutic ultrasound in the pre-implantation phase. METHODS: pregnant Wistar female rats have been exposed to 3 MHz, 0.6 W/cm² ultrasound, pulsatile ultrasound (PUS) or continuous ultrasound (CUS), and controls, unplugged ultrasound (UUS), for five minutes. The rats were sacrificed at the 20th day post-insemination. Biochemical and hematological analyses have been done. Animals have been submitted to necropsy in order to identify lesions of internal organs, and to remove and weight the liver, kidneys and ovaries. Alive, malformed, dead and reabsorbed fetuses have been counted. RESULTS: the rats have not presented changes in their body and organs weight, and neither in their reproductive capacity, but there has been an increase in triglycerides in the PUS and CUS groups, when compared to the UUS group. The fetuses' relative weights of the heart (0.7 ± 0.9), liver (9.8 ± 0.8), kidneys (6.2 ± 0.8) and lungs (3.8 ± 0.4) increased in the CUS, when compared to the heart (0.7 ± 0.9), liver (9.8 ± 0.8), kidneys (6.2 ± 0.8) e lungs (3.8 ± 0.4) of the UUS. CONCLUSIONS: in the experimental model, the therapeutic ultrasound used has not caused meaningful maternal toxicity. Pulsatile waves have not changed fetal morphology, but continuous waves have caused increase in the relative weight of the fetuses' heart, liver, lungs and kidneys.